|
Patent landscape, scope, and claims: |
US Patent 6,180,639 (HIV): Scope of Claims and Patent Landscape
US 6,180,639 is directed to HIV treatment using a specific stereochemically defined anti-HIV compound, formulated as a pharmaceutical composition and co-administered with, or sequenced relative to, a second antiviral agent. The enforceable core is the use of the (−)-enantiomer of cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one while constraining the (+) enantiomer content in the administered composition to no more than 5% w/w (with dependent claim tiers at ≤2% and ≤1%). The second agent is broadly defined (acyclic nucleosides, interferons, renal excretion inhibitors, nucleoside transport inhibitors, dideoxynucleosides, immunomodulators, erythropoietin, Ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or CD4-binding inhibitors). Dosage ranges are captured both in mg and mg/kg.
What is the claim scope, in enforceable terms?
1) What is the first active: a single compound defined by stereochemistry
Across the claim set, the “compound” is consistently:
- (−)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (or a pharmaceutically acceptable salt)
The patent places strict limits on impurity stereoisomer content in the delivered product, stated as a percent of the (+) enantiomer relative to total (−)+(+) enantiomers.
2) What stereochemical boundary drives infringement risk
Independent claim 1 (and parallel independent claims for compositions) requires:
- (+) enantiomer present ≤ 5% w/w, relative to the combined weight of the (−) and (+) enantiomers.
Dependent tiers tighten the boundary:
- Claim 6 / 23 / 32 / 34 / 44 / 45 / 25 / 26: (+) ≤ 2% w/w
- Claim 7 / 24 / 33 / 35 / 45 (tier) / 26 (tier): (+) ≤ 1% w/w
Practical read-through: the patent’s claim coverage is not only “use this compound,” but “use this compound with controlled enantiomeric purity.” Product-specification compliance is therefore directly material.
3) What the second antiviral agent covers
Claim 2 defines a closed list of example categories/actives. The second agent is stated as “another agent having antiviral activity” and is specifically enumerated as one of:
- acyclic nucleoside
- interferon
- renal excretion inhibitor
- nucleoside transport inhibitor
- 2′,3′-dideoxynucleoside
- immunomodulator
- erythropoietin
- Ampligen
- thyomodulin
- thymopentin
- foscarnet
- ribavirin
- inhibitor of HIV binding to CD4
This enumeration matters because it narrows the “another agent” concept to the listed types/agents rather than a purely open-ended “any antiviral.”
4) What administration patterns are claimed
The patent captures three administration regimes:
- Simultaneous administration (Claim 9 and variants)
- Sequential administration (Claim 8 and variants)
- In combination (Claim 46, 47, 48 and variants)
The independent “method” claim 1 already covers administering a composition containing both the first compound (at enantiomeric purity) and the second agent, but dependent claims also seek additional leverage via timing (sequential vs simultaneous) and “combination” phrasing.
5) What dosage ranges are claimed
Dosage appears in mg (per composition) and mg/kg (per day). The key ranges:
These ranges are broad in the upper bounds and tightly anchored in the “typical dosing band” at 1–20 mg/kg/day.
How are the claims structured to maximize coverage?
A) Independent claim families: methods, compositions, and combinations
The text you provided includes multiple independent/near-independent claim groupings:
- Method of treatment: Claim 1
- Method of treatment with essentially the same limitation stack: Claim 49
- Pharmaceutical composition: Claim 13
- Composition variants: Claims 53 and later
- Combination: Claim 57
- Article of manufacture: Claims 61–64 (packaged multi-amount concept)
Each family replicates the same key constraint:
- First compound is the (−) enantiomer (or salt)
- Product contains ≤5% (+) enantiomer (with dependent cutoffs at ≤2% and ≤1%)
- Second antiviral agent is from the enumerated list
- Carried in a pharmaceutically acceptable carrier (for composition claims)
- Treatment targets a human suffering from HIV infection
B) Dependent claims stack three types of limitations
- Agent identity: Claim 2 and dependent analogs (Claim 14, 19, 51, 55, 56, 59, 60, 63, 64)
- Dose/amount: Claims 3–5 and 10–12 and related mg/kg and mg windows
- Stereochemical impurity levels: Claims 6–7 and 23–26 and later duplicates
This stacking increases the likelihood that at least one “route” (composition amount, dosage band, or purity band) matches a real-world product and regimen.
What is the practical infringement map (what would trigger coverage)?
1) Product enantiomeric specification is a primary gate
Coverage is conditioned on the (+) enantiomer percentage in the delivered composition.
- If the administered formulation contains >5% w/w (+) enantiomer, it avoids the independent claim baseline and likely avoids dependent claims as well (since dependent tiers sit below 5%).
- If it is within ≤5%, further differentiation exists for ≤2% and ≤1%, giving the patentee multiple fallback positions.
2) The second agent must be one of the enumerated categories
If the second agent is outside the listed set (or outside the defined “inhibitor of HIV binding to CD4” scope as used in the patent), claims 2 and its dependent analogs will not be met.
3) Timing can matter, but the composition claims also cover co-formulated regimens
- If both agents are in a single pharmaceutical composition delivered together, composition claims (and method claims with the “composition comprising” framing) are implicated.
- If agents are delivered as two separate products, the sequential/simultaneous/combination language in dependent claims creates additional paths to infringement.
4) Dosage windows are broad; many regimens will fall inside
The mg/kg/day range is expansive at the top end (up to 750 mg/kg/day) and has a mid-band at 1–20 mg/kg/day. Similarly, mg-per-composition ranges cover small and larger tablet/capsule or unit-dosed formulations.
What does the claim text imply about claim breadth (strong vs narrow areas)?
Breadth is high on:
- the first compound class (actually a single structure, but with salts allowed)
- dosing windows (broad upper and overlapping dependent bands)
- administration timing (multiple regimes claimed)
- stereochemical impurity tolerance at 5% w/w
Breadth is constrained on:
- the second antiviral agent list (enumerated set)
- the stereochemical boundary (must be ≤5% (+))
What is the patent landscape around US 6,180,639?
Landscape conclusion based on the claim content you provided
The claim set is tailored to a specific stereodefined anti-HIV compound and its use in combination therapy. This creates three landscape zones that typically matter for freedom-to-operate analyses for this kind of patent:
-
Stereospecific composition / impurity-control patents
The defining novelty is the (+) enantiomer cap (≤5%, and dependent ≤2%/≤1%). Other patents in the same program family often cover:
- preparation methods for controlling enantiomeric purity
- salt forms and formulations
- analytical methods to measure enantiomeric composition
-
Combination-therapy patents with established HIV co-therapies
The second-agent list shows the patentee expected real-world use with standard HIV pharmacology classes (nucleoside analogs, transport/excretion modulators, interferons, immunomodulators, ribavirin, foscarnet, CD4 binding inhibition). The landscape typically includes:
- separate patents on using the first compound in combination with specific classes
- later patents refining timing (sequential vs simultaneous), dosing ratios, and patient subsets
-
Dosage-form patents
The claim includes “pharmaceutical composition” and “article of manufacture” language. The landscape likely includes formulation-focused continuations:
- unit dose packaging
- co-pack/dispenser kits with two amounts (first amount of enantiomerically-purified compound + second amount of another antiviral)
Key inference for competitive strategy
For a generic or follow-on developer, the dominant landscape risk is the stereochemical spec. Many developers can meet API identity but struggle with stereochemical impurity specs across scale-up batches. For an innovator, landscape risk is more likely in:
- using the same (−) compound with the same co-therapy classes while meeting the same enantiomeric purity caps, and
- dosing within the claimed mg or mg/kg bands.
Claim-by-claim coverage highlights (most leverage in enforcement)
| Claim group |
Limitation that sets the hook |
Coverage width |
| Claim 1 (method) |
HIV treatment + composition with (−) compound + antiviral agent + (+) ≤5% w/w |
High, because purity and agent list are both required but dosing is flexible |
| Claim 6-7 (purity tiers) |
(+) ≤2% and (+) ≤1% |
Creates strong dependent fallbacks |
| Claim 2 (agent list) |
Second agent limited to enumerated antivirals/classes |
Narrower than a generic “any antiviral” claim |
| Claims 3-5 and 10-12 (dose ranges) |
mg and mg/kg/day windows |
Broad enough to catch many regimens |
| Claims 8-9, 46-48 (timing) |
sequential vs simultaneous vs “in combination” |
Broadens infringement theories |
| Claims 13, 53 (composition claims) |
pharmaceutically acceptable carrier + first compound + antiviral agent + (+) ≤5% |
Covers co-formulated products even if timing differs |
| Claims 61-64 (article of manufacture) |
packaged “first amount” with enantiomeric cap + “second amount” of antiviral |
Adds leverage against kit/co-pack strategies |
Key Takeaways
- US 6,180,639 is built around stereochemical purity: the delivered composition must contain ≤5% w/w (+) enantiomer, with dependent tiers at ≤2% and ≤1%. This is the central, high-value infringement lever.
- Combination therapy is required, but the second agent is enumerated (acyclic nucleosides, interferons, transport/excretion modifiers, dideoxynucleosides, immunomodulators including erythropoietin/Ampligen/thyomodulin/thymopentin, foscarnet, ribavirin, and CD4-binding inhibitors).
- Timing is covered multiple ways (simultaneous, sequential, and “in combination”), and dose ranges are broad (mg-per-composition and mg/kg/day), which raises the probability that common clinical regimens fit at least one claim pathway.
- The landscape risk for competitors clusters around enantiomeric-spec control and combination regimens, especially for any product that can satisfy both the stereochemical cap and the enumerated co-therapy categories.
FAQs
-
Does US 6,180,639 require the (+) enantiomer to be absent?
No. It requires the (+) enantiomer content to be no more than 5% w/w, with dependent claims tightening to ≤2% and ≤1%.
-
Is any antiviral allowed as the “another agent”?
No. The “another agent” is limited to the enumerated list in the claims (e.g., acyclic nucleosides, interferons, nucleoside transport inhibitors, dideoxynucleosides, immunomodulators including Ampligen/thyomodulin/thymopentin, foscarnet, ribavirin, and CD4-binding inhibitors).
-
Are both method-of-treatment and composition claims present?
Yes. The patent includes method claims (treating HIV patients) and pharmaceutical composition claims (carrier + first compound + another antiviral agent with the (+) enantiomer cap).
-
Do the claims cover both simultaneous and sequential dosing?
Yes. Dependent claims explicitly cover simultaneous administration and sequential administration, plus “in combination” language.
-
Where is the highest practical risk for generic or follow-on products?
The highest-risk variable is typically the enantiomeric purity specification (meeting ≤5% and potentially ≤2%/≤1%), combined with selecting an eligible second antiviral from the claim list and dosing within the claimed windows.
References (APA)
[1] US Patent No. 6,180,639. (n.d.). Method and composition for treating HIV infection with enantiomerically controlled compound and antiviral agent.
More… ↓
⤷ Start Trial
|
